<産業資料/調査レポートの題名> 2022年7月19日

抗真菌薬の世界市場2018-2022


◆英文タイトル:Global Antifungal Drugs Market 2018-2022

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Fungal infection pipeline
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
• Segmentation by route of administration
• Comparison by route of administration
• Topical – Market size and forecast 2017-2022
• Oral – Market size and forecast 2017-2022
• Parenteral – Market size and forecast 2017-2022
• Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Vendors covered
PART 15: VENDOR ANALYSIS
• Market positioning of vendors
• Astellas Pharma
• Basilea Pharmaceutica
• Merck
• Pfizer
PART 16: APPENDIX
• List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global antifungals treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Late-stage pipeline drugs against fungal infections
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global antifungal drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global antifungal drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Route of administration – Market share 2017-2022 (%)
Exhibit 20: Comparison by route of administration
Exhibit 21: Topical – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Topical – Year-over-year growth 2018-2022 (%)
Exhibit 23: Oral – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Oral – Year-over-year growth 2018-2022 (%)
Exhibit 25: Parenteral – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Parenteral – Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Global antifungal drugs market – Market share by geography 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Market opportunity
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Vendor overview
Exhibit 47: Astellas Pharma – Business segments
Exhibit 48: Astellas Pharma – Organizational developments
Exhibit 49: Astellas Pharma – Geographic focus
Exhibit 50: Astellas Pharma – Key offerings
Exhibit 51: Vendor overview
Exhibit 52: Basilea Pharmaceutica – Business segments
Exhibit 53: Basilea Pharmaceutica – Organizational developments
Exhibit 54: Basilea Pharmaceutica – Geographic focus
Exhibit 55: Basilea Pharmaceutica – Key offerings
Exhibit 56: Vendor overview
Exhibit 57: Merck – Business segments
Exhibit 58: Merck– Organizational developments
Exhibit 59: Merck – Geographic focus
Exhibit 60: Merck – Segment focus
Exhibit 61: Merck – Key offerings
Exhibit 62: Vendor overview
Exhibit 63: Pfizer – Business segments
Exhibit 64: Pfizer – Organizational developments
Exhibit 65: Pfizer – Geographic focus
Exhibit 66: Pfizer – Segment focus
Exhibit 67: Pfizer – Key offerings


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark